Fda panel recommends approval of benlysta® for treating systemic lupus

Fda panel recommends approval of benlysta® for treating systemic lupus

On November 16, the US Food and Drug Administration (FDA) Arthritis Advisory Committee voted overwhelmingly (13 to 2) to recommend BENLYSTA® for approval as a treatment for the autoimmune disease lupus. If ultimately approved by FDA , BENLYSTA would become the first new treatment for lupus in 52 years. While the vote was a positive step, the FDA still must make a final decision to approve BENLYSTA in the coming weeks. Following the panel’s vote, Dr. Gary S. Gilkeson, Chair of the LFA Medical-Scientific Advisory Council, and Sandra C. Raymond, LFA President and CEO, presented comments on the s…



Fda panel recommends approval of benlysta® for treating systemic lupus